<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="93195"><DrugName>BTK inhibitors (hematologic malignancies/autoimmune disorders, oral), Principia</DrugName><DrugSynonyms><Name><Value>BTK inhibitors (hematologic malignancies/autoimmune disorders, oral), Principia</Value></Name><Name><Value>PRN-473</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1054078">Principia Biopharma Inc</CompanyOriginator><CompaniesPrimary><Company id="1054078">Principia Biopharma Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1054078" type="Company"><TargetEntity id="5034759295" type="organizationId">Principia Biopharma Inc</TargetEntity></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"></TargetEntity><TargetEntity id="D019337" type="MeSH"></TargetEntity><TargetEntity id="-105358819" type="omicsDisease"></TargetEntity><TargetEntity id="1328" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"></TargetEntity><TargetEntity id="D001327" type="MeSH"></TargetEntity><TargetEntity id="-2072222280" type="omicsDisease"></TargetEntity><TargetEntity id="729" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3592" type="Action"><TargetEntity id="1668" type="Mechanism">Bruton's Tyrosine Kinase (BTK) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00229" type="ciTarget"><TargetEntity id="6158038666953" type="siTarget">Tyrosine-protein kinase BTK</TargetEntity><TargetEntity id="93" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="2054">Hematological neoplasm</Indication><Indication id="36">Autoimmune disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="3592">Btk tyrosine kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-05-20T06:32:48.000Z</LastModificationDate><ChangeDateLast>2018-04-06T00:00:00.000Z</ChangeDateLast><AddedDate>2014-11-03T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1054078" linkType="Company"&gt;Principia Biopharma&lt;/ulink&gt; is investigating Bruton's (Btk) tyrosine kinase inhibitors, developed based on Principia's reversible, tailored covalency platform, for the potential oral treatment of hematologic malignancies, and including PRN-473 for the potential treatment of autoimmune diseases [&lt;ulink linkID="1602582" linkType="Reference"&gt;1602582&lt;/ulink&gt;], [&lt;ulink linkID="1672695" linkType="Reference"&gt;1672695&lt;/ulink&gt;]. In May 2015, preclinical data were presented [&lt;ulink linkID="1672695" linkType="Reference"&gt;1672695&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2016, preclinical data were presented at the 74th AAD Annual Meeting in Washington DC. In dogs, treatment with PRN-473 (approximately 15 mg/kg, qd, po, tablets or crushed into food) resulted in a pronounced reduction in the skin disease activity in the first weeks. PRN-473 was well tolerated with no changes in laboratory parameters [&lt;ulink linkID="1741839" linkType="Reference"&gt;1741839&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 2015 AAI Annual Meeting in New Orleans, LA. In  mouse and rat collagen-induced arthritis  model, PRN-473 was demonstrated to be  therapeutically effective as the drug dose-dependently inhibited BTK, with reversal of arthritis and preserved joint integrity. No organ specific toxicity was reported [&lt;ulink linkID="1672695" linkType="Reference"&gt;1672695&lt;/ulink&gt;]. In March 2018, similar data were presented at the 255th ACS National Meeting and Exposition in New Orleans, LA, PRN-473 had an IC50 value of 0.6 nM and occupancies of 46 (OCC 24h (biochemical)) and 32% (OCC 24h /cellular) [&lt;ulink linkID="2013287" linkType="Reference"&gt;2013287&lt;/ulink&gt;], [&lt;ulink linkID="2016324" linkType="Reference"&gt;2016324&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1054078">Principia Biopharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2015-07-14T00:00:00.000Z</StatusDate><Source id="1672695" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1054078">Principia Biopharma Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2014-10-16T00:00:00.000Z</StatusDate><Source id="1602582" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-00229"><Name>Btk tyrosine kinase</Name><SwissprotNumbers><Swissprot>P35991</Swissprot><Swissprot>Q06187</Swissprot><Swissprot>Q8JH64</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Chemical Structure Added/Updated</Reason><Description>Chemical structure added/updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CC(C)(C)/C=C(\C#N)/C(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4F)Oc5ccccc5)c(ncn3)N</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>